104 results about "Serum uric acid level" patented technology

(Aza)indolizine derivatives represented by Formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In Formula (I), 0 to 2 of X1, X2, X3 and X4 are a nitrogen atom and the others are CR1; one of T1 and T2 represents cyano and the other represents a group represented by Formula (A), with the proviso that when T1 is cyano, at least one of X1 to X4 is a nitrogen atom; R1 independently represents a hydrogen atom, a halogen atom, a hydroxy group, C1-6 alkyl, C1-6 alkoxy or the like; ring U represents a benzene ring or the like; m represents integral number from 0 to 2; R2 independently represents a fluorine atom, a hydroxy group or the like.

The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

The present invention relates to lactic acid bacteria with an effect of uric acid level reducing in blood. According to the present invention, various lactic acid bacteria are cultured in the presence of a purine; a consumption amount of the purine and a production amount of purine decomposition products are determined; multiple lactic acid bacteria with significant purine decomposing abilities are selected; the selected lactic acid bacteria are adopted to orally feed rats, general statuses and serum uric acid levels of the rats are determined, and influence on the serum uric acid level due to the lactic acid bacteria feeding is researched, wherein the selected lactic acid bacteria are judged as the lactic acid bacteria having high purine decomposing abilities, and the rats are fed with a purine-containing feed; and two lactic acid bacteria capable of significantly inhibiting serum uric acid level increasing are found, wherein the two lactic acid bacteria are Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779.

The present invention relates to a novel purpose of mangiferin compound for preventing and remedying hyperuricemia and gout. A study shows that the mangiferin compound has very strong anti-gout effect; 0.002mmol / kg (0.78mg / kg) of the dosage can reduce the serum uric acid level of a mouse with the hyperuricemia obviously; the mangiferin compound has higher activity than allopurinol and has little toxic and side effect; the maximum gastric infusion tolerance dose of the mouse is 47.4mmol / kg (20g / kg), which is lower than that of current clinical applied anti-gout medicines, such as colchicines, the allopurinol, sulphinpyrazone, etc.; the present invention can be applied to prepare for oral anti-gout medicines and health care products.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, haloalkyl and the like; X1 and X2 independently represent CR2 or N; R2 represents H, alkyl and the like; R1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M)2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO2 and the like.

The present invention provides a composition comprising at least one microorganism selected from the group consisting of lactic acid bacteria and yeasts that have an ability to decompose purines and an action of lowering serum uric acid level and in particular, such a composition in a food, beverage or pharmaceutical form. Such a composition is effective in the prevention and amelioration of hyperuricemia.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

Provided is a method for obtaining a lactic acid bacterium having a property of reducing a serum uric acid level. The present invention relates to: a method for screening for a lactic acid bacterium, which comprises determining the amount of a purine body incorporated in each of lactic acid bacteria in a culture medium containing the purine body and then screening for a lactic acid bacterium having a property of trapping the purine body among the lactic acid bacteria employing the amount as a measure; and a purine body trapping agent for reducing a serum uric acid level, which comprises a lactic acid bacterium obtained by the method.

The invention provides a composition and application of the composition in the preparation of medicaments, health-care food or functional food for preventing and treating hyperuricemia. The composition comprises at least one of holothuria saponins and holothuria polysaccharides, wherein the holothuria saponins are main secondary metabolites in holothuria, and have various physiological and pharmacological activity of hemolysis, fungus resistance, cytotoxicity, tumor resistance, immunoregulation, antioxidation, blood fat reduction and the like and have high medicinal value; the holothuria polysaccharides are important ingredients of holothuria body walls, and have the pharmacological activity of anticoagulation, thrombus resistance, tumor resistance, immunoregulation and the like. Animal experiments prove that the prepared composition containing at least one of the holothuria saponins and the holothuria polysaccharides can improve the serum uric acid level of animals in vivo obviously so as to prevent and treat the hyperuricemia.

The invention discloses a saury maillard peptide with a uric acid reducing function as well as a preparation method and an application of the saury maillard peptide. The preparation method of the saury maillard peptide comprises the steps as follows: saury is minced, heated and stirred, the pH value is regulated to 4.2, centrifugal separation is performed, precipitates are taken, protease is added to the precipitates for enzymolysis, an enzyme product is centrifuged, and the supernatant is taken and filtered by an ultrafiltration membrane to obtain a saury peptide liquid; the concentrated saury peptide liquid is added with reducing sugar for reaction, and the saury maillard peptide is obtained. The method is combined with a biological enzymolysis technology, a biological membrane technology and a maillard reaction technology, biological active peptide with uric acid reducing activity is released from saury protein, target active peptide is enriched through the ultrafiltration membrane, and finally, the uric acid reducing activity of the target biological active peptide is improved with the maillard reaction technology. The saury maillard peptide prepared with the method has the remarkable uric acid reducing function, the serum uric acid level of mice with hyperuricemia induced by oteracil potassium can be remarkably reduced, and the saury maillard peptide has the remarkable kidney protection function.

The invention concretely relates to an edible plant dryer, comprising a water extraction dry paste of Chinese herbal medicines and activated herb residues, wherein the Chinese herbal medicines comprise Houttuynia Cordata, Chinese soapberry, tea stalks and cassia seeds. The edible plant dryer has a good antibacterial moisture-absorption effect and the detection result of the edible plant dryer by a Societe Generale de Surveillance (SGS) agency shows that: the antibacterial effect level of the dryer is the first level; and the moisture absorption effect is as large as 2.5 times of the ordinary silica gel. The edible plant dryer has no harm on a human body and is also not dangerous even after the dryer is eaten by mistaken; and in addition, the moisture absorption effect is good, thus the edible plant dryer can be widely applied in the food and daily chemical industry fields. Moreover, the edible plant dryer also has the function of reducing the level of the serum uric acid of the mice with hyperuricemia and also reducing the serum total cholesterol of the rat with hyperlipidemia.

The invention discloses a building method of an acute hyperuricemia renal damage mouse model. The method comprises the following steps of experiment mice are subjected to molding experiment for many days by using xanthine, ethambutol and oteracil potassium as molding agents; obtaining the acute hyperuricemia renal damage mouse model; observing the body weight, the serum uric acid level and the renal function change of the experiment mice and the kidney pathological change; the renal damage effect of the molding agent on the experiment mice is analyzed. The mice are used as model animals; the serum uric acid level of the mice is equivalent to the uric acid level of a hyperuricemia patient; the serum uric acid level is stable and can easily reappear; meanwhile, the combined effect of uric acid precursors of hypoxanthine is used; the uric acid excreted substances of ethambutol and uricase inhibitors of oteracil potassium are reduced; the acute hyperuricemia renal damage mouse model is built; the molding time is short; the model conforms to the clinical characteristics of human body hyperuricemia renal damage, and is applicable to screening hyperuricemia renal damage resisting medicine.

The invention provides combined application of nuciferine and analogue thereof and a drug. The drug is used for treating or preventing hyperuricemia and reducing the serum uric acid level.

The invention discloses a plant composition for treating hyperuricemia and gout and plant composition solid granules. The plant composition is prepared from celery seed extract, corn silk powder, pumpkin powder, lotus leaf powder, mulberry powder, ginseng powder grape powder by mixing. The plant composition solid granules are mainly prepared from the plant composition. According to the plant composition for treating the hyperuricemia and the gout and the plant composition solid granules, the celery seed extract, the corn silk powder, the pumpkin powder, the lotus leaf powder, the mulberry powder, the ginseng powder and the grape powder are compounded for use to improve the nutritional compositions, and the celery seed extract can significantly reduce the serum uric acid level and the urineuric acid level of the hyperuricemia; the corn silk powder and the lotus leaf powder can accelerate urinary excretion and help uric acid excretion; and the pumpkin powder, the mulberry powder, the ginseng powder and the grape powder have the functions of nourishing the liver and kidney, enhancing immunity and protecting the liver and kidney. The action mechanism of each component is different, multi-component mixing effectively exerts the synergistic effect between the components, the action time is prolonged, the curative effect is enhanced, and the components are homologous to medicine andfood, are safe and have no side effects.

The invention discloses lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1131 can reduce the serum uric acid level of a hyperuricemia mouse, inhibit the xanthine oxidase (XOD) activity of serum and the liver, and reduce the occurrence of hyperuricemia and gout; the lactobacillus rhamnosus CCFM1131 can be used for down-regulating serum blood sugar, down-regulating serum total triglyceride (TG), down-regulating serum total cholesterol (TC) level and inhibiting serum alkaline phosphatase (ALP) activity; in addition, the lactobacillus rhamnosus CCFM1131 can promote the expression of the ileum uric acid transporter ABCG2. Besides, the lactobacillus rhamnosus CCFM1131 can tolerate gastrointestinaltract environment, can be used for preparing functional microbial inoculants, foods and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

The invention discloses a common seepweed herb tea substitute, and relates to tea substitutes. The common seepweed herb tea substitute comprises common seepweed herb, germinated brown rice, chicory root and unripe tangerine peel. The prepared common-seepweed-herb germinated-brown-rice unripe-tangerine-peel tea is yellowish green and bright in color, and organically integrates aroma of tea and rice; the common seepweed herb tea substitute preserves natural aroma of the common seepweed herb and the chicory, and is added with fragrance of the unpolished brown rice. And thus, the common seepweed herb tea substitute is fresh, mellow and palatable in flavor, as well as aromatic and thick in tea soup. The common seepweed herb tea substitute has greatly increased nutritional values and flavor, andis very characteristic in tea aroma; moreover, the common seepweed herb tea substitute has fragrance of the common seepweed herb, the unripe tangerine peel and the rice, and contains water-soluble polyphenols of the common seepweed herb, rich amino acids, minerals, a large amount of vitamin B and vitamin E and the like. And thus, the common seepweed herb tea substitute is capable of eliminating stress so as to make people relaxed, conditioning the constitution, promoting blood circulation, increasing intestinal peristalsis, lubricating the intestines, relaxing the bowels, relieving inflammation, and moistening dryness; moreover, the common seepweed herb tea substitute has the functions of resolving food stagnation and strengthening the spleen and the stomach, and is capable of improving serum uric acid level of the human body. And thus, the common seepweed herb tea substitute is an ideal drink for people with hypertension and hyperlipidemia.

The invention discloses the application of a flos chrysanthemi indici extract. Linarin is contained in the flos chrysanthemi indici extract, the mass percent of the linarin is not smaller than 50 percent, the application of the flos chrysanthemi indici extract is as follows: the flos chrysanthemi indici extract is used for preventing or curing hyperuricemia. According to the invention, through the combination of the linarin contained in the flos chrysanthemi indici extract, the characteristic of lowering xanthine oxidase activity can be achieved, and the flos chrysanthemi indici extract can be used for preventing or curing hyperuricemia, can remarkably lower the serum uric acid level of a model rat, can lower the levels of serum creatinine and urea nitrogen, has the advantages of easiness in component separation, controllability in quality, low additive dose, remarkable effects and the like, and has a great and profound significance in improving human health.

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. That is, the present invention relates to indolizine derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In the formula, ring U represents aryl or heteroaryl; R1 represents halogen, a hydroxy group or the like; R2 represents halogen, a hydroxy group, alkyl, alkoxy, alkyl substituted by fluorine, alkoxy substituted by fluorine or the like; m represents a number from 0 to 2; n represents a number from 0 to 3; and R3 represents hydrogen, fluorine or the like.

The invention relates to the field of medicines, and particularly discloses application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout. The invention also provides capsules and sustained-release tablets for preventing and treating hyperuricemia and gout. The invention discovers that 5,6,7,4'-tetrahydroxy flavone and derivatives thereof have strong anti-gout action, can significantly reduce the serum uric acid level of mouse suffering from hyperuricemia at low dosage, have activity equivalent to that of allopurinol, have low toxic and side effects, have safety higher than that of anti-gout drugs such as colchicine, allopurinol and anturan used clinically at present, can be used for preparing drugs for preventing and treating hyperuricemia and gout, and have broad clinical application prospects.

The invention discloses a constructing method for a subacute hyperuricemia renal damage mouse model. The method comprises the following steps that yeast cream and oteracil potassium are taken as a molding agent, a molding experiment is constantly carried out on an experiment mouse for multiple days, a subacute hyperuricemia renal damage mouse model is acquired, wherein during the molding experiment process, the yeast cream is given to the experiment mouse every day, and after the yeast cream is given to the experiment mouse in the last day of the molding experiment, the oteracil potassium is given to the experiment mouse; the weight, serum uric acid level, renal function change and renal pathology change of the experiment mouse are observed, and damage of the molding agent to the experiment mouse is analyzed. According to the constructing method, the mouse is taken as a model animal, the yeast cream in which a uric acid precusor substance is added for a long term is adopted, the oteracil potassium as a uricase inhibitor is taken as the molding agent and is used, and the subacute hyperuricemia renal damage mouse model with stable effect is in accordance with clinical features and issuccessfully constructed.

The invention discloses combined application of gallnut catechin or catechin gallate or gallnut catechin gallate and salt capable of being pharmaceutically accepted and gallic acid to treating hyperuricemia. A catechin compound has the strong in-vitro inhibition effect on xanthine oxidase, the serum uric acid level of a mouse suffering from hyperuricemia can be obviously reduced, and the catechin compound can serve as a potential xanthine oxidase inhibitor and a uric acid reduction medicine to be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia.

The invention provides an eurycoma longifolia jack (eurycoma longifolia jack) extract and a preparation method and application thereof. The eurycoma longifolia jack extract contains a eurycoma longifolia jack diterpene component of which the percentage by weight is 85%-95%. The eurycoma longifolia jack diterpene component disclosed by the invention has the effects of reducing the serum uric acid level of an experiment high-uric-acid animal model and promoting excretion of uric acid, and is hopeful to be further developed into a medicine for treating high uric acid.

The invention discloses an application of a benzopyran derivative represented as the formula (I) and a pharmaceutically acceptable salt thereof in preparation of drugs for treating hyperuricaemia. The benzopyran derivative not only has strong in-vitro inhibition effect on xanthine oxidase but also can significantly reduce the serum uric acid level of mice suffered from the hyperuricaemia. The benzopyran derivative has dose-dependent, is free of toxic and side effects, is good in safety and can be used as a potential xanthine oxidase inhibitor and a uric acid reducing medicine for treating the hyperuricaemia and gout or gout complications caused by the hyperuricaemia.

5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, haloalkyl and the like; X1 and X2 independently represent CR2 or N; R2 represents H, alkyl and the like; R1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, —N(-D-L-M)2 and the like, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO2 and the like.

The invention relates to a novel purpose of a Polyrhachis vicina Roger alcohol extract and an aqueous extract for preventing and treating gout. The research shows that the Polyrhachis vicina Roger alcohol extract or the aqueous extract possesses strong anti-gout effect, the alcohol extract (4g crude drug / kg, 2g crude drug / kg) and the aqueous extract (4g crude drug / kg) substantially reduce the hyperuricemia mice serum uric acid level, have no substantial influence on normal mice serum uric acid level, and can substantially inhibit the toe swelling induced by sodium urate, the activity and allopurinol are equal, and the toxic and side effect are small. Mice take Polyrhachis vicina Roger alcohol extract LD50 is 54.64g crude drug / kg, 95% of reliability of LD50 is 48.36 crude drug / kg-61.73 crude drug / kg; mice take Polyrhachis vicina Roger aqueous extract LD50 is 69.82g crude drug / kg, 95% of reliability of LD50 is 66.73 crude drug / kg-73.04 crude drug / kg. The Polyrhachis vicina Roger extract can be used for preparing anti-gout medicines and health products.